oryzatensin has been researched along with Neoplasms* in 1 studies
1 other study(ies) available for oryzatensin and Neoplasms
Article | Year |
---|---|
Oryzatensin-stimulated PBMCs Increase Cancer Progression In-vitro.
Oryzatensin (ORZ) can reduce potentially IFN-γ secretion by natural killer (NK) cells. Therefore, current study was designed to evaluate the effects of ORZ treatment on peripheral blood mono-nuclear cells (PBMCs) cytokine secretion, proliferation and also to evaluate vascular endothelial growth factor (VEGF) and Matrix Metalloproteinase 9 (MMP-9) expression in HEP-G2 cell line after culture with ORZ-stimulated PBMCs. In this ex-vivo study, PBMCs from apparently healthy male volunteers (n=25) aged 20-30 were isolated by ficoll density gradient. Tetrazolium colorimetric test (MTT assay), ELISA test and real time PCR were performed to evaluate PBMCs proliferation, PBMCs cytokine secretion and the genes expression accordingly. The results of MTT assay showed that ORZ significantly stimulated proliferation of the isolated PBMCs. The results also indicated that ORZ treatment significantly decrease and increase IFN-γ and IL-4 secretion by isolated PBMCs, respectively. Also, VEGF and MMP-9 expression significantly increased in HEP-G2 cells after culture with ORZstimulated PBMCs. The previous studies have introduced ORZ-like peptide for pharmacological purpose and in this study we get to the conclusion that the administration of this peptide may change the immune system response and sensitize target populations to cancer. Topics: Adult; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cytokines; Disease Progression; Enzyme-Linked Immunosorbent Assay; Humans; Immune System; Interferon-gamma; Leukocytes, Mononuclear; Male; Neoplasms; Oligopeptides; Young Adult | 2017 |